CPIC指南:CYP2D6、CYP2C19、CYP2B6、SLC6A4及HTR2A基因型与5-羟色胺再摄取抑制剂类抗抑郁药
该指南更新并扩展了2015年CPIC关于CYP2D6和CYP2C19基因型与SSRI剂量的指南,总结了CYP2D6、CYP2C19、CYP2B6、SLC6A4和HTR2A基因型对多种5-羟色胺再摄取抑制剂类抗抑郁药剂量、疗效和耐受性的影响。指南提供了利用CYP2D6、CYP2C19和CYP2B6基因型结果辅助处方的推荐,并指出SLC6A4和HTR2A的现有数据不支持其用于抗抑郁药处方。
要点
- CYP2D6、CYP2C19和CYP2B6基因型影响多种抗抑郁药代谢,可指导剂量选择。
- SLC6A4和HTR2A基因型现有数据不支持用于抗抑郁药处方。
- 本指南更新并扩展2015年CPIC指南,涵盖更多药物和基因。
核心结论
- CYP2D6、CYP2C19和CYP2B6基因型结果可用于辅助5-羟色胺再摄取抑制剂类抗抑郁药的处方决策。
- SLC6A4和HTR2A基因型的现有数据不支持其临床用于抗抑郁药处方。
研究设计与样本
- 制定机构:临床药物遗传学实施联盟(CPIC)。
- 方法:基于证据综述更新并扩展2015年CPIC指南,总结五个基因与抗抑郁药剂量、疗效和耐受性的关系。
主要发现
- CYP2D6、CYP2C19和CYP2B6的遗传变异影响多种5-羟色胺再摄取抑制剂类抗抑郁药的代谢,可能影响剂量、疗效和耐受性。
- SLC6A4(5-羟色胺转运体)和HTR2A(5-羟色胺2A受体)基因与疗效及副作用谱的关系已有研究,但现有数据不支持其临床用于处方。
关键数值与推荐
- 推荐使用CYP2D6、CYP2C19和CYP2B6基因型结果辅助处方5-羟色胺再摄取抑制剂类抗抑郁药。
- SLC6A4和HTR2A基因型不推荐用于抗抑郁药处方。
临床怎么用
- 临床处方5-羟色胺再摄取抑制剂类抗抑郁药时,可参考CYP2D6、CYP2C19和CYP2B6基因型结果调整用药决策。
- 不应基于SLC6A4或HTR2A基因型进行抗抑郁药处方决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (i.e., desvenlafaxine, duloxetine, levomilnacipran, milnacipran, and venlafaxine), and serotonin modulators with SSRI-like properties (i.e., vilazodone and vortioxetine) are primary pharmacologic treatments for major depressive and anxiety disorders. Genetic variation in CYP2D6, CYP2C19, and CYP2B6 influences the metabolism of many of these antidepressants, which may potentially affect dosing, efficacy, and tolerability. In addition, the pharmacodynamic genes SLC6A4 (serotonin transporter) and HTR2A (serotonin-2A receptor) have been examined in relation to efficacy and side effect profiles of these drugs. This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability. We provide recommendations for using CYP2D6, CYP2C19, and CYP2B6 genotype results to help inform prescribing these antidepressants and describe the existing data for SLC6A4 and HTR2A, which do not support their clinical use in antidepressant prescribing.
引用
- Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023. PMID: 37032427. doi:10.1002/cpt.2903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。